Cotinga Pharmaceuticals Inc. is the new name of Critical Outcome Technologies Inc.
The expected effective date of the name change is January 10, 2018.

Cotinga Pharmaceuticals Inc. (Cotinga) is a clinical-stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer.

Cotinga uses proprietary artificial intelligence technologies to pursue a targeted and transformational approach to treating cancer and other unmet medical needs. Cotinga’s CHEMSAS® technology accelerates the discovery and development of novel drug therapies, allowing Cotinga to build a pipeline of potential drug candidates faster and with a higher probability of success than traditional methods.

Investor Overview

Cotinga’s lead compound, COTI-2, has a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. P53 mutations occur in over 50% of all cancers. COTI-2 is initially being evaluated for the treatment of gynecologic cancers and head and neck squamous cell carcinoma in a Phase 1 clinical trial at the MD Anderson Cancer Center at the University of Texas and the Lurie Cancer Center at Northwestern University. Cotinga has secured orphan drug status in the United States for COTI-2 for the treatment of ovarian cancer. Preclinical data suggests that COTI-2 could dramatically improve the treatment of cancers with mutations in the p53 gene.

Cotinga’s second lead compound, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS function. KRAS mutations occur in up to 30% of all cancers and represent a tremendous unmet clinical need and a desirable drug target.  COTI-219 is currently undergoing testing in support of an investigational new drug (“IND”) filing.

Cotinga Pharmaceuticals Inc. is a publicly traded company listed in Canada on the TSX Venture Exchange under the symbol COT, and in the United States on the OTCQB Venture Marketplace under the symbol COTQF.

Cotinga files electronically certain continuous disclosure documents on the System for Electronic Document Analysis and Retrieval (SEDAR) which can be accessed at  The preceding link will open a new browser window and take you directly to the SEDAR website.